Additionally, patients with lower m5Cscore exhibited more therapeutic efficiency on anti-CTLA4 therapy in LIHC, while the combination of anti-CTLA4 therapy and pd1 was more efficient for PAAD patients with a lower m5C score (Figure 6g). Here, CTLA4 is linked to pancreatic adenocarcinoma.